Low cyclosporine concentrations in children and time to acute graft versus host disease

BMC Pediatrics

Table 2 Univariate and multivariate logistic regression analysis to identify predictors of acute GVHD related to cyclosporine administration

Characteristics	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Characteristics	Unadjusted OR (95% CI)	Model I	Model II	Model III
Age ≥ 12 (years)	0.474 (0.163–1.375)	1.444 (0.294–7.081)	4.936 (0.413–59.061)	2.447 (0.22–27.203)
Male	0.987 (0.357–2.729)	1.585 (0.389–6.468)	1.626 (0.23–11.471)	1.102 (0.164–7.393)
Mismatched donor	1.633 (0.476–5.600)	1.693 (0.358–7.996)	0.582 (0.04–8.524)	1.479 (0.175–12.480)
Myeloablative conditioning regimen	0.612 (0.206–1.822)	0.376 (0.084–1.692)	0.162 (0.018–1.450)	0.146 (0.022–0.989)^*
Methotrexate	0.267 (0.072–0.993)^*	0.264 (0.041–1.721)	0.158 (0.009–2.830)
Kidney injury grade 0–1 (NCI CTCAE)	8.000 (1.556–41.134)^*	9.828 (1.434–67.339)^*	1.800 (0.184–17.596)
Low CsA concentrations at lag time before aGVHD
Lag 0–6 days	9.286 (2.882–29.917)^***	11.017 (2.336–51.947)^**
Lag 7–13 days	58.556 (10.632–322.499)^***		108.196 (7.725–1515.48)^***
Lag 14–20 days	11.111 (1.976–62.466)^***			12.120 (1.064–138.13)^*

Model I included age, sex, mismatched donor, myeloablative conditioning regimen, methotrexate use, kidney injury (NCI CTCAE grade 2 or higher), and low CsA concentrations at lag days 0–6 before aGVHD. After considering multicollinearity, Model II and III included low CsA concentrations at lag days 7–13 and 14–20 days, respectively
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, CsA cyclosporine, aGVHD acute graft-versus-host disease, OR odds ratio
^*P < 0.05, ^**P < 0.01, ^***P < 0.001

ISSN: 1471-2431